Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“Day 2 ASH25 abstract selection:
2/10 ASH Abstract: New data alert!
A novel biparatopic nanobody-based BCMA CAR-T combined with pomalidomide shows promising potency for RRMM: In-vitro characterisation and phase 1 dose-escalation study. Here’s what you need to know.
Another study from China
Why this matters: RRMM remains tough to treat. Current BCMA CAR-T therapies work well—but many patients still relapse. Adding pomalidomide (an IMiD) could boost CAR-T performance.
Takeaway: This biparatopic BCMA CAR-T plus pomalidomide combo shows:
- Superior in-vitro potency
- Manageable safety
- Deep MRD-negative responses
Next stop → Phase 2 evaluation.
Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study.”
More posts featuring Al-Ola A Abdallah.